Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "BSE"

973 News Found

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial
Clinical Trials | February 22, 2026

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns


GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly
Clinical Trials | February 19, 2026

GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly

The data highlights its RSV vaccine cuts hospitalizations in older adults


Pfizer’s BRAFTOVI regimen shows major breakthrough in aggressive colorectal cancer
Clinical Trials | February 18, 2026

Pfizer’s BRAFTOVI regimen shows major breakthrough in aggressive colorectal cancer

BREAKWATER is a Phase 3, randomized, open-label trial testing BRAFTOVI in combination with cetuximab, either alone or with chemotherapy, in patients with untreated BRAF V600E-mutant mCRC


Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer
Clinical Trials | February 17, 2026

Lilly’s Retevmo shows major survival boost in early-stage RET fusion lung cancer

The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease


HanchorBio scores first FDA orphan drug tag for gastric cancer therapy
Biotech | February 17, 2026

HanchorBio scores first FDA orphan drug tag for gastric cancer therapy

The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients


Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Clinical Trials | February 17, 2026

Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD

Duvakitug was well tolerated and safety was consistent with the induction study


Moderna’s new Covid vaccine mNEXSPIKE wins European approval
News | February 17, 2026

Moderna’s new Covid vaccine mNEXSPIKE wins European approval

mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe


Lundbeck’s bocunebart shows breakthrough potential in migraine prevention
Clinical Trials | February 16, 2026

Lundbeck’s bocunebart shows breakthrough potential in migraine prevention

Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide


Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
News | February 09, 2026

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26